Ruxolitinib
APICAS: 941678-49-5
Sample Stock:
Ruxolitinib is a prescription medication that works by inhibiting Janus kinase (JAK) enzymes, specifically JAK1 and JAK2. This targeted action interferes with abnormal signaling pathways that drive certain blood disorders and inflammatory conditions.
Related Information
Purity:98%+
Registration:GMP/DMF
Biological Profile
Biological Targets
JAK1·JAK2
Associated Conditions
alopecia areata·kidney disease·acute myeloid leukemia·Myelofibrosis·head and neck squamous cell carcinoma·
Key Intermediates
4 Items| Structure | Name | CAS No. | Sample Stock | MDL No. | Details |
|---|---|---|---|---|---|
 | 1-(1-Ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | 1029716-44-6 | MFCD11857753 | ||
 | 3-Cyclopentylacrylonitrile | 591769-05-0 | MFCD11857755 | ||
![(4-(1-(2-Cyano-1-cyclopentylethyl)-1h-pyrazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate structure](https://static.dempochem.com/structures-bw/6936994db361a16e65aafaaf.svg) | (4-(1-(2-Cyano-1-cyclopentylethyl)-1h-pyrazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate | 1236033-05-8 | - | ||
 | Ruxolitinib Phosphate | 1092939-17-7 | MFCD18452860 |